ePrints

S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility

Lookup NU author(s): Professor Quentin AnsteeORCiD, Professor Chris Day

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

S-adenosyl-L-methionine (SAMe; Ado Met) is an important, metabolically pleiotropic molecule that participates in multiple cellular reactions as the precursor for the synthesis of glutathione and principle methyl donor required for methylation of nucleic acids, phospholipids, histones, biogenic amines, and proteins. SAMe synthesis is depressed in chronic liver disease and so there has been considerable interest in the utility of SAMe to ameliorate disease severity. Despite encouraging pre-clinical data confirming that SAMe depletion can exacerbate liver injury and supporting a hepatoprotective role for SAMe therapy, to date no large, high-quality randomised clinical trials have been performed that establish clinical utility in specific disease states. Here, we offer an in-depth review of the published scientific literature relating to the physiological and pathophysiological roles of SAMe and its therapeutic use in liver disease, critically assessing implications for clinical practice and offering recommendations for further research. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Publication metadata

Author(s): Anstee QM, Day CP

Publication type: Review

Publication status: Published

Journal: Journal of Hepatology

Year: 2012

Volume: 57

Issue: 5

Pages: 1097-1109

Print publication date: 01/11/2012

ISSN (print): 0168-8278

ISSN (electronic): 1600-0641

Publisher: ELSEVIER SCIENCE BV

URL: http://dx.doi.org/10.1016/j.jhep.2012.04.041

DOI: 10.1016/j.jhep.2012.04.041

Share